Omnipod Horizon™ Automated Glucose Control System

DEVICE4 trials

Sponsors

Insulet Corporation

Conditions

Type 1 DiabetesType 1 Diabetes Mellitus

Unknown Phase

Prepivotal Omnipod Horizon™ Automated Glucose Control System

CompletedNCT04176731

Insulet CorporationType 1 Diabetes Mellitus

Start: 2019-12-15End: 2020-01-31Updated: 2023-11-13

Pivotal Omnipod Horizon™ Automated Glucose Control System

CompletedNCT04196140

Insulet CorporationType 1 Diabetes Mellitus

Start: 2019-12-30End: 2022-04-20Updated: 2025-04-03

Continuous Glucose Monitoring System (CGM)-Informed Bolus Calculator Study

CompletedNCT04320069

Insulet CorporationType 1 Diabetes

Start: 2020-06-09End: 2020-09-29Updated: 2023-11-13

Omnipod Horizon™ Automated Glucose Control System Preschool Cohort

CompletedNCT04476472

Insulet CorporationType 1 Diabetes Mellitus

Start: 2020-09-08End: 2022-10-12Updated: 2024-02-14

Related Papers

Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod <sup>®</sup> 5 Automated Insulin Delivery System

Diabetes Technology & Therapeutics2024-01-2620 citations

Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes

Diabetes Technology & Therapeutics2023-10-1832 citations

Psychosocial Outcomes with the Omnipod® 5 Automated Insulin Delivery System in Children and Adolescents with Type 1 Diabetes and Their Caregivers

Pediatric Diabetes2023-06-2913 citations

How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod® 5 System

Diabetes Research and Clinical Practice2022-07-1652 citations

Clinical Evaluation of a Novel CGM-Informed Bolus Calculator with Automatic Glucose Trend Adjustment

Diabetes Technology & Therapeutics2021-09-079 citations